The Board of Active Biotech AB has decided to accept Carl Bennet AB’s public offer on shares in Lifco AB at the price of 42 SEK per share.
The shares will be transfered in accordance with the offer.
Active Biotech’s shareholding amounts to 1 812 103 Lifco serie B, corresponding to 19,9% of the capital and 12,5% of the votes.
The stockholding is a financial asset and a capital gain of 11,0 MSEK will arise upon sale.
Lund 2 August 2000
Active Biotech AB (publ)
Sven Andréasson
President & CEO